Griseofulvin is contraindicated in patients with porphyria. Dosage has not been established. After administration, fosaprepitant is rapidly converted to aprepitant. Moderate Use caution if griseofulvin and aprepitant are used concurrently and monitor for a possible decrease in the efficacy of aprepitant. Print this section Print the entire contents of. Keep using this medicine for the full treatment time, even if you feel better after the first few doses.
Always consult your doctor or pharmacist. Although this interaction has not been studied, predictions about the interaction can be made based on the metabolic pathways of griseofulvin and telaprevir.
Inducers of CYP3A4 may decrease the concentration of doxorubicin and compromise the efficacy of chemotherapy. Controlled studies in pregnant women show no evidence of fetal risk. Of note, concurrent use has resulted in reduced oral contraceptive efficacy. If concurrent use is necessary, closely monitor patients for signs or symptoms of skin toxicity. Griseofulvin is marketed in several oral formulations in an attempt to increase bioavailability and decrease GI intolerance.
Non-Medicare Plans Medicare Plans. Patients should avoid sunlight UV exposure via intense natural or artificial sunlight.
Most commonly, these are "non-preferred" brand drugs or specialty prescription products. Raritan, NJ Distributed by: Major Coadministration of griseofulvin with atazanavir is not recommended. This hypersensitivity is manifested by urticaria, other rashes, and, rarely, angioedema and a reaction resembling serum sickness. Tier Description 1 This drug is available at the lowest co-pay.
Usual Adult Dose for Onychomycosis - Fingernail
The use of the drug is not justified in minor or trivial infections which will respond to topical anti-fungal agents alone. This may precipitate an attack of acute intermittent porphyria in susceptible patients. For children, griseofulvin therapy can be difficult to adhere to.
Smaller particle sizes result in an enhanced effect. Individual plans may vary and formulary information changes.